Welcome to our dedicated page for Corvex SEC filings (Ticker: MOVE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Movano Inc. (Nasdaq: MOVE) SEC filings page on Stock Titan provides direct access to the company’s official regulatory disclosures, along with AI-powered summaries that help explain their contents in plain language. Movano, doing business as Movano Health, files a range of documents with the U.S. Securities and Exchange Commission that together outline its wearable health technology business, capital structure, and significant corporate events.
Investors can review registration statements such as the Form S-1 that describes a committed equity facility with Chardan Capital Markets LLC, including the potential issuance of up to 110,000,000 shares of common stock under the facility and Movano’s status as an emerging growth company and smaller reporting company. The S-1 and related materials also discuss Nasdaq listing matters, reverse stock split effects on share counts, and stockholders’ equity considerations.
Current reports on Form 8-K document material events, including the Agreement and Plan of Merger with Corvex, Inc., the structure of the all-stock combination, expected ownership percentages of the combined company, and conditions to closing. Other 8-K filings cover the one-for-ten reverse stock split, Nasdaq deficiency notices and extensions, amendments to incentive plans, preferred stock financings, amendments to loan agreements, and stockholder meeting results. These filings provide detail on how Movano is addressing listing requirements, financing needs, and its planned transformation through the Corvex merger.
Definitive proxy statements on Schedule 14A offer insight into stockholder votes on matters such as increasing authorized share capital, approving share issuances under the ChEF Purchase Agreement, amending the omnibus incentive plan, and authorizing reverse stock splits. They also describe virtual special meeting logistics and voting procedures for common and preferred stockholders.
On Stock Titan, each filing is accompanied by AI-generated highlights that point out key terms, risk factors, and structural details, helping users navigate lengthy documents like S-1 registration statements and complex 8-K merger disclosures. The platform also makes it easier to locate quarterly and annual reports when filed (Forms 10-Q and 10-K), as well as any insider transaction reports on Form 4, so users can monitor executive and director share dealings once available.
By using this page, investors can quickly find Movano’s official SEC filings related to its wearable medical devices, financing arrangements, Nasdaq compliance efforts, and the proposed renaming and repositioning of the company as Corvex, Inc. after the merger closes, while relying on AI tools to surface the most important information from each document.
Movano Inc. (MOVE) filed an insider trading report showing its Chief Executive Officer and director, John Mastrototaro, receiving additional equity compensation. On January 9, 2026, he was granted 11,919 shares of common stock at a price of $0.00 per share, reported as a receipt of restricted stock units under the company’s Omnibus Incentive Plan. The grant was made in lieu of cash salary for the period from January 1, 2026 to March 31, 2026. Following this award, Mastrototaro beneficially owned 16,349 shares of Movano common stock, held directly.
Movano Inc. filed an S-1 covering the resale of up to 110,000,000 shares of common stock that may be issued to Chardan under a committed equity facility, plus 545,456 shares issuable on conversion of Series A Preferred Stock held by selling stockholders. Movano is not selling shares itself in this prospectus and will not receive proceeds from resales by these holders.
The Series A financing provided $3.0 million of bridge capital through 3,000 Series A Preferred shares, automatically convertible into common stock at $5.50 per share in connection with a planned merger with AI infrastructure company Corvex. Under the merger agreement, Corvex is expected to become a wholly owned subsidiary and the combined company will be renamed Corvex, Inc., with Corvex holders projected to own about 94.8% of the post‑merger equity and current Movano holders about 5.2%.
Movano recently effected a one‑for‑ten reverse split and faces Nasdaq delisting risk after reporting stockholders’ equity of approximately $(1.701) million versus the $2.5 million requirement. Nasdaq has granted an extension to March 30, 2026 to regain compliance, but there is no assurance this will be achieved.
Movano Inc. director Emily Fairbairn reported equity compensation and holdings in company stock. On January 9, 2026, she received grants of 4,470 restricted stock units (RSUs) under the company’s Omnibus Incentive Plan in lieu of cash directors’ fees for the period from January 1, 2026 to June 30, 2026, and a separate grant of 5,959 RSUs for the same period. Both grants were reported at a price of $0 per share, reflecting that they are non-cash awards.
Following these awards, Fairbairn reported 13,119 shares of Movano common stock held directly. She also reported indirect holdings of 33,232 shares held by the Malcolm P. Fairbairn and Emily T. Fairbairn Charitable Remainder Unitrust, over which she has voting and investment power while disclaiming beneficial ownership except for her and her spouse’s pecuniary interest, and 3,522 shares held by Valley High Limited Partnership, over which she also has voting and investment power.
Movano Inc. director Brian Cullinan reported stock-based compensation. On January 9, 2026, he received two grants tied to service under the company’s Omnibus Incentive Plan for the period from January 1, 2026 to June 30, 2026.
The filing shows a grant of 4,768 restricted stock units (RSUs) in lieu of cash directors’ fees for that period, and a separate grant of 2,980 RSUs for the same service period. Both entries are recorded at a price of $0.00 per share. After these awards, Cullinan is shown as beneficially owning 9,622 shares of Movano common stock, held directly.
Movano Inc. director Ruben Caballero reported receiving equity compensation instead of cash fees. On January 9, 2026, he acquired 2,980 shares of common stock at $0 per share, with the footnote explaining this reflects a grant of 2,980 restricted stock units (RSUs) under the Omnibus Incentive Plan in lieu of cash directors’ fees for the period from January 1, 2026 to June 30, 2026. A second transaction that same day reports another acquisition of 2,980 shares at $0 per share, tied to a separate grant of 2,980 RSUs for the same period. Following these grants, Caballero beneficially owned 6,495 shares of Movano common stock directly.
Movano Inc. director Shaheen Wirk reported stock-based compensation rather than a cash payment. On January 9, 2026, Wirk received a grant of 2,980 restricted stock units (RSUs) under Movano’s Omnibus Incentive Plan in lieu of cash directors’ fees for the period from January 1, 2026 to June 30, 2026. On the same date, Wirk received a separate grant of 2,980 RSUs under the same plan for service over that same January 1, 2026 to June 30, 2026 period.
Both transactions are reported at a price of $0 per share, reflecting equity compensation rather than a market purchase. Following these grants, Wirk is shown as beneficially owning 5,860 shares of Movano common stock directly.
Movano Inc. director and Chief Technology Officer Michael Aaron Leabman reported exercising stock options and related share sales. On January 6, 2026, he exercised 42,250 stock options at an exercise price of $1.25 per share, receiving the same number of Movano common shares. On January 7, 8, and 9, 2026, he sold 3,293, 3,593, and 783 shares, respectively, at weighted average prices of $7.34, $7.26, and $7.27 per share, with the filing noting that shares were sold to pay withholding taxes and exercise costs tied to option awards received in lieu of 2025 cash salary. After these transactions, Leabman directly held 34,937 shares of Movano common stock. The filing also states that the option award became exercisable following shareholder approval of an amendment to the Omnibus Incentive Plan on December 16, 2025.
Movano Inc. CFO Jeremy Cogan reported several equity transactions. On January 5, 2026, he exercised 20,000 stock options at an exercise price of $1.25 per share, converting them into common stock. That same day, he sold 1,879 common shares at a weighted average price of $8.35, with actual prices ranging from $8.00 to $8.61, to cover withholding taxes and exercise costs tied to option awards received in lieu of 2025 cash salary.
On January 6, 2026, he sold 3,859 shares at a weighted average price of $8.03 and 4,359 shares at a weighted average price of $7.57, also in multiple trades within stated price ranges for tax and exercise obligations. On January 9, 2026, he received a grant of 9,299 restricted stock units (RSUs) in lieu of salary for the period from January 1, 2026 to March 31, 2026. After these transactions, he directly owned 24,406 shares of common stock and held 64,834 stock options.
Movano Inc. has a planned insider sale of 10,097 shares of its Class A common stock under Rule 144. The shares are to be sold through J.P. Morgan Securities LLC on the NYSE, with an aggregate market value of 79,119 stated for this block. The filing notes the shares were acquired from Movano Inc. via a cashless option exercise and sale, with 84,834 securities acquired in that transaction and the purchase price paid in cash.
Movano Inc. reported an insider transaction by Chief Executive Officer and director John Mastrototaro on January 5, 2026. He exercised 5,000 stock options with a $1.25 exercise price, receiving 5,000 shares of common stock. On the same day, he sold 2,514 common shares at $8.21 per share to cover withholding taxes and exercise costs related to stock option awards granted in lieu of cash salary during 2025.
Following these transactions, Mastrototaro directly owned 4,430 shares of Movano common stock and 72,834 stock options. The option exercised on January 5, 2026 had been granted contingent on shareholder approval of an amendment to the Omnibus Incentive Plan, which was approved on December 16, 2025, making the option exercisable.